請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/64221完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 江文章(Wen-chang Chiang) | |
| dc.contributor.author | Ling-Hui Huang | en |
| dc.contributor.author | 黃鈴惠 | zh_TW |
| dc.date.accessioned | 2021-06-16T17:35:30Z | - |
| dc.date.available | 2017-08-28 | |
| dc.date.copyright | 2012-08-28 | |
| dc.date.issued | 2012 | |
| dc.date.submitted | 2012-08-15 | |
| dc.identifier.citation | 行政院衛生署。2012。台灣地區死因統計結果摘要及衛生統計。
六城雅彙、西原哲三、浮田忠之進、井口定男。1950。各種藥物の吉田肉腫にする增殖阻止作用。Gann (Japanese J. Cancer Res.) 41, 91-92. 中山宗春。1960。薏苡仁抗癌作用之研究。日本外科學會誌。61, 234。 吳宛穎。2000。糙薏仁對第二型糖尿病病人血糖及血脂肪的影響。國立臺灣海洋 大學品科學研究所碩士論文。基隆。 吳雅婷。2011。薏苡殼萃取物在體外及體內試驗對於雄烯二酮分泌的影響。國立 臺灣大學食品科技研究所碩士論文。臺北。 杜姿瑩。1999。糙薏仁降血脂作用之研究。國立臺灣大學食品科技研究所碩士論文。 臺北。 李鳳云，陳浩然，馮曉東，柳世英，姜力。1994。中藥薏苡仁抗腫瘤作用的研究。 實用腫瘤學雜誌。3:59。 李大鵬。1996。康萊特注射液治療原發性肺癌臨床報告。中醫雜誌。37, 411-414。 李明怡。2008。薏仁麩皮中防癌及抗發炎活性成分之分離與鑑定。國立臺灣大學食 品科技研究所博士論文。臺北。 施宛宜。2001。以細胞模式探討薏苡籽實萃取物對COX-2和iNOS之表現的影響。 國立臺灣大學食品科技研究所碩士論文。臺北。 施純光。2004。薏仁對大腸癌形成之影響。國立臺灣大學食品科技研究所博士論 文。臺北。 林靜慧。2007。薏苡籽實乙醇萃取物及其次區分層對人類癌細胞生長之影響。國 立臺灣大學食品科技研究所碩士論文。臺北。 徐明麗，1997。薏仁抗過敏及抗腫瘤之研究。國立臺灣大學食品科技研究所碩士論文。臺北。 徐志穎。2010。薏仁麩皮乙醇萃取物乙酸乙酯區分層對於人類乳癌細胞生長之影 響。國立臺灣大學食品科技研究所碩士論文。台北。 許倖華，2008。薏仁麩皮乙醇萃取之乙酸乙酯層區分物對DMH誘發F344鼠大腸 癌前期病變之預防效果。國立臺灣大學食品科技研究所碩士論文。台北。 陳欣喬。2009。薏苡麩皮乙醇萃取物正己烷區分層之成分分析與純化鑑定。國立 臺灣大學食品科技研究所碩士論文。台北。 高德錚，梁純玲。1986。省產薏仁品質之檢定。臺中農業改良場研究彙報。13, 11-18。 夏詩閔。2001。薏苡籽實萃取物對大鼠卵巢性類固醇激素、腦下腺黃體促素和濾泡 刺激素分泌之效應。國立臺灣大學食品科技研究所碩士論文。臺北。 夏詩閔。2006。薏苡麩皮及薏苡殼甲醇萃取物對大鼠卵巢顆粒細胞分泌孕酮之效 應。國立臺灣大學食品科技研究所博士論文。臺北。 曾勝雄，江文章，王思涓，蘇慧美。2003。不同產地及儲藏溫度對薏仁成分及特 殊生理機能性成分之影響。臺中區農業改良場研究彙報。80, 25-39。 曾怡雯。2004。薏苡籽實萃取物對大鼠萊氏細胞分泌睪固酮的效應。國立臺灣大學 食品科技研究所碩士論文。臺北。 雷正杰，張忠義，王鵬，吳惠勤。1999。薏苡仁油脂肪酸組成分析。中藥材。22, 405。 郭靜娟。2001。薏苡籽實之抗氧化成分及其抑制自由基傷害之研究。國立臺灣大學 食品科技研究所博士論文。台北。 黃羌維，陳由強。1987。薏苡營養成分和產地環境條件的關係。植物生理通訊。4, 36-39。 黃士禮，陳瑤峰，江文章。1994。省產薏苡籽實中氨基酸、脂肪酸和一組成分分 析。食品科學。21, 67-74。 黃士禮。1996。薏苡籽實儲藏條件、抗突變效應、及抗腫瘤效果之研究國立臺灣 大學食品科技研究所博士論文。臺北。 黃士禮。1996。薏苡籽實貯藏條件、抗突變效應及抗腫瘤效應之研究。國立臺灣大 學食品科技研究所博士論文。台北。 黃士禮，江文章。1999。薏苡籽實各部分之化學組成分及其丙酮萃取液之抗致突變 效應。食品科學。26, 121-130。 黃博偉。2003。不同糙薏仁成分對糖尿病大白鼠醣代謝及脂質代謝的影響國立臺 灣大學食品科技研究所博士論文。臺北。 黃鼎文。2010。薏苡籽實萃取物之抗氧化和抗發炎活性成分及其抗動脈硬化危險 因子之效果。國立臺灣大學食品科技研究所博士論文。臺北。 詹璐齊。2008。小米與糙薏仁對非固醇類抗發炎藥物誘導大鼠急性胃黏膜損傷之 保護效果。國立臺灣大學食品科技研究所碩士論文。臺北。 楊啟春，顏慧貞，張曙明，江文章。1995。省產薏仁澱粉理化性質之探討食品科 學。22, 113-123。 蔡至宏。1997。薏苡種皮水溶性物質之抗致突變性及其分離與純化。國立臺灣大 學食品科技研究所碩士論文。臺北。 劉家余。2010。薏仁麩皮萃取物乙酸乙酯區分層之抗發炎效果。國立臺灣大學食 品科技研究所碩士論文。臺北。 鍾成沛。2011。薏仁麩皮乙醇萃取物之活性篩選及其乙酸乙酯區分層之化學組成 研究。國立臺灣大學食品科技研究所博士論文。臺北。 簡雅琳。1998。薏苡殼油溶性萃取物的抗突變性成分之分離與純化。國立臺灣大 學食品科技研究所碩士論文。臺北。 蘇珮琪。1996。薏仁對高血脂症和糖尿症病患血漿脂質和血糖的影響。輔仁大學 食品營養學系碩士論文。臺北。 Altenberg, G. A.; Vanoye, C. G.; Horton, J. K.; Reuss, L. Unidirectional fluxes of rhodamine 123 in multidrug-resistant cells: evidence against direct drug extrusion from the plasma membrane. Cell Biology. 1994, 91, 4654-4657. Ambudkar, S. V.; Kimchi, S. C.; Sauna, Z. E.; Gottesman, M. M. P-glycoprotein: from genomics to mechanism. Oncogene. 2003, 22, 7468-7485. Aoki, M. and Tuzihara, N. Effects of the hatomugi (Coix lachryma-jobi L. var.ma-yuen) on the hyperlipidemia in rats. 日本家政學会誌。1985, 36, 27-33. Awad, A. B.; Fink, C. S.; Williams, H.; Kim, U. In vitro and in vivo (SCID mice) effects of phytosterols on the growth and dissemination of human prostate cancer PC-3cells. Eur J Cancer Prev. 2001, 10, 507-513. Awad, A. B.; Burr, A. T.; Fink, C. S. Effect of resveratrol and β-sitosterol in combination on reactive oxygen species and prostaglandin release by PC-3 cells. Prostaglandins Leukot Essent Fatty Acids. 2005, 72, 219-226. Awad, A. B.; Chinnam, M.; Fink, C.S; Bradford, P.G. β-Sitosterol activates Fas signaling in human breast cancer cells. Phytomedicine. 2007, 14, 747-754. Basini, G.; Bussolati, S.; Santini, S. E.; Bianchi, F.; Careri, M.; Mangia, A.; Musci, M.; Grasselli, F. Antiangiogenesis in swine ovarian follicle: Apotential role for2-methoxyestradiol. Steroids. 2007, 72, 660-665. Basu, S.; Bayoumy, S.; Zhang, Y.; Lozano, J.; Kolesnick , R. BAD enables ceramide to signal apoptosis via Ras and Raf-1. J Biol Chem. 1998, 273, 30419-30426. Benjamin, R. S. Clinical pharmacology of Adriamycin (NSC-123127). Cancer Chemother Rep. 1975, 6, 183-185. Bernards, R.; Weinberg, R. A. Metastasis genes: A progression puzzle. Nature. 2002, 418, 823. Biersack, H.; Jensen, S.; Gromova, I.; Nielsen, I. S.; Westergaard, O.; Andersen, A. H.Active heterodimers are formed from human DNA topoisomerase II alpha and II beta isoforms. Biochemistry.1996, 93, 8288-8293. Billingham, M. E.; Bristow, M. R.; Glatstein, E.; Mason, J. W.; Masek, M. A.; Daniels, J. R. Adriamycin cardiotoxicity: endomyocardial biopsy evidence of enhancement by irradiation. Am J Surg Pathol. 1977, 1, 17-23. Biersack, H.; Jensen, S.; Gromova, I.; Nielsen, I. S.; Westergaard, O.; Andersen, A. H.Active heterodimers are formed from human DNA topoisomerase II alpha and II beta isoforms. Biochemistry.1996, 93, 8288-8293. Blaner, W. S.; Hendriks, H. F.; Brouwer, A.; de Leeuw, A. M.; Knook, D. L.; Goodman, D. S. Retinoids, retinoid-binding proteins, and retinyl palmitate hydrolase distributions in different types of rat liver cells. J Lipid Res. 1985, 26, 1241-1251. Block, S.; Baccelli, C.; Tinant ,B.; Meervelt, L.; Rozenberg, R.; Jiwan, J. L.; Llabres G.; Pauw-Gillet, M. C.; Quetin-Leclercq J. Diterpenes from the leaves of Croton zambesicus. Phytochemistry. 2004, 65, 1165-1172. Borman, L. S.; Bornmann, W. G.; Kuehne, M. E. Modulation of drug cytotoxicity in wild-type and multidrug-resistant tumor cells by stereoisomeric series of C-20'-vinblastine congeners that lack antimicrotubule activity. Cancer Chemother Pharmacol 1993, 31, 343-349. Bratton, S. B.; MacFarlane, M.; Cain, K.; Cohen, G.M. Protein complexes activate distinct caspase cascades in death receptor and stress-induced apoptosis. Exp. Cell Res. 2000, 256, 27-33. Brian P. S. Gene therapy to protect haematopoietic cells from cytotoxic cancer drugs. Nature Reviews Cancer. 2002, 2, 431-441. Bristow, M. R.; Anthracycline cardiotoxicity. In: Bristow MR, ed. Drug induced heart disease. New York: Elsevier. 1980, 191-215. Castedo, M.; Perfettini, J. L.; Roumier, T.; Valent, A.; Raslova, H.; Yakushijin, K.; Horne, D.; Feunteun, J.; Lenoir, G.; Medema, R.; Vainchenker, W.; Kroemer, G. Mitotic catastrophe constitutes a special case of apoptosis whose suppression entails aneuploidy. Oncogene. 2004, 23, 4362-4370. Chang, K. C.; Duh, C.Y.; Chen, I. S.; Tsai, I. L. A. Cytotoxic butenolide, two new dolabellane diterpenoids, a chroman and a benzoquinol derivative Formosan Casearia membranacea. Planta Med. 2003, 69, 667-672. Chen, G. K.; Lacayo, N. J.; Dura’n, G. E.; Wang, Y.; Bangs, C. D.; Rea , S.; Kovacs, Mary.; Cherry, A. M.; Brown, J. M.; Sikic , B. I. Preferential expression of a mutant allele of the amplified MDR1 (ABCB1) gene in drug-resistant variants of a human sarcoma. Genes, Chromosomes & Cancer 2002, 34, 372-383. Chen, F.; Wang, T.; Wang, J.; Wang, Z. Q.; Qian, M. Levistolide A overcomes P-glycoprotein-mediated drug resistance in human breast carcinoma cells. Acta Pharmacol Sin. 2008, 29, 458-464. Chiang, W.; Cheng, C. Y.; Chiang, M. T.; Chung K. T. Effects of dehulled adlay on the culture count of some microbiota and their metabolism in the gastrointestinal tract of rats. J. Agric. Food Chem. 2000, 48, 829-832. Choi, J.; Lee, E.; Lee, H.; Kim, K.; Ahn, K.; Shim, B. Identification of campesterol from Chrysanthemum coronarium L and its antiangiogenic activities. Phytother Res 2007, 21, 954-959. Chou, J. H.; Chang, T. T.; Chou, T. C. Models for drug development and drug resistance. The Cancer Handbook 2005, 67, 1-16. Chou, T. C. Theoreticalbasis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacological Reviews. 2006, 58, 621-681. Chou, T. C. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Research. 2010, 70, 440-446. De Stefani, E.; Boffetta, P.; Ronco, A. L.; Brennan, P.; Deneo-Pellegrini H.; Carzoglio J.C. Plant sterols and risk of stomach cancer: A case-control study in Uruguay. Nutr Cancer. 2000, 37, 140-144. Fahy, D. M.; O'Callaghan, Y. C.; O'Brien, N. M. Phytosterols: lack of cytotoxicity but interference with beta-carotene uptake in Caco-2 cells in culture. Food Addit Contam.2004, 21, 42-51. Feller, N.; Kuiper, C. M.; Lankelma, J.; Ruhdal, J. K.; Scheper, R. J.; Pinedo, H. M.; Broxterman, H. J. Functional detection of MDR1/P170 and MRP/P190-mediated multidrug resistance in tumour cells by flow cytometry. Br J Cancer. 1995, 72: 543-549. Gewirtz, D. A. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem. Pharmacol. 1999, 57, 727-741. Gilladoga, A. C.; Manuel, C.; Tan, C. T.; Wollner, N.; Sternberg, S. S.; Murphy, M. L. The cardiotoxicity of Adriamycin and daunomycin in children. Cancer. 1976, 37, 1070-1078. Gosland, M. P.; Lum, B. L.; Sikic, B. I. Reversal by cefoperazone of resistance to etoposide, doxorubicin, and vinblastine in multidrug resistant human sarcoma cells. Cancer Res 1989,49, 6901- 6905. Gros, P.; Croop, J.; Housman, D. Mammalian multidrug resistance gene: Complete cDNA sequence indicates strong homology to bacterial transport proteins. Cell. 1986, 47, 371-380. Han, J. S.; Rhee, A. H.; Cheigh, H. S. A study on composition of polar lipid in adlay. Korean J Food Soc Technol. 1987, 16, 29-35. Hanahan D.; Weinberg R. A. The hallmarks of cancer. Cell. 2000, 100, 57-70. Harker, W. G.; Sikic, B. I. Multidrug (pleiotropic) resistance in doxorubicin-selected variants of the human sarcoma cell line MES-SA. Cancer Res 1985, 45, 4091-4096. Hengartner, M.O. The biochemistry of apoptosis. Nature. 2000, 407, 770-776. Herr, I.; Debatin, K. M. Cellular stress response and apoptosis in cancer therapy. Blood. 2001, 98, 2603-2614. Houghton, P. J.; Retsas, S.;Photiou, A.,;Jackson, S. J. In Vitro Cytotoxicity of Norviburtinal and Isopinnatal from Kigelia pinnata Against Cancer Cell Lines. Planta Med. 2000, 66, 758-761. Hsu, H. F.; Huang, K. H.; Lu, K. J.; Chiou, S. J.; Yen, J. H.; Chang, C. C.; Houng, J. Y. Typhonium blumei extract inhibits proliferation of human lung adenocarcinoma A-549 cells via induction of cell cycle arrest and apoptosis. J .Ethmopharmacol. 2011, 135, 492-500. Ju, Y. H.; Clausen, L. M.; Allred, K. F.; Almada, A. L.; Helferich, W. G. β-Sitosterol, β-sitosterol glucoside, and a mixture of β-sitosterol and β-sitosterol glucoside modulate the growth of estrogenresponsive breast cancer cells in vitro and ovariectomized athymic mice. J Nutr. 2004, 134, 1145-1151. Kerr, J. F.; Wyllie, A. H.; Currie, A. R: Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer. 1972, 26, 239-257, 1972. Kim, Y. D.; Lees, D. E.; Lake, C. R. Hyperthermia potentiates doxorubicin- related cardiotoxic effects. JAMA. 1979, 241,1816-1817. Kim, D. W.; Kim, K. O.; Shin, M. J.; Ha, J. H.; Seo, S. W.; Yang, J.; Lee, F. Y. siRNA-based targeting of antiapoptotic genes can reverse chemoresistance in P- glycoprotein expressing chondrosarcoma cells. Molecular Cancer. 2009, 8：28. Kim, H. S.; Lee, Y. S.; Kim, D. K.; Doxorubicin exerts cytotoxic effects through cellcycle arrest and fas-mediated cell death. Pharmacology. 2009, 84, 300-309. Kondo, Y.; Kanzawa, T.; Sawaya, R.; Kondo, S. The role of autophagy in cancer development and response to therapy. Nature Reviews Cancer 2005, 5, 726-734. Koo J. S.; Choi , W. C.; Rhee, Y. H,; Lee, H. J.; Lee, E. O.; Ahn, K. S.; Bae, H. S.; Ahn, K. S.; Kang, J. M.; Choi, S. U.; Kim, M. O.; Lu, J.; Kim, S. H. Quinoline derivative KB3-1 potentiates paclitaxel induced cytotoxicity and cycle arrest via multidrug resistance reversal in MES-SA/Dx5 cancer cells. Life Sciences. 2008, 83, 700-708 Kowaltowski, A. J.; Castilho, R. F.; Vercesi, A. E. Opening of the mitochondrial permeability transition pore by uncoupling or inorganic phosphate in the presence of Ca2+ is dependent on mitochondrial- generated reactive oxygen species. FEBS Letters. 1996, 378, 150-152. Kroemer, G.; Petit, P. X.; Zamzami, N.; Vayssiere, J. L.; Mignotte, B. The biochemistry of programmed cell death. FASEB J. 1995, 13, 1277-1287. Kwon, J. I.; Kim, G. Y.; Park, K.Y.; Ryu, C. H.; Choi, Y. H. Induction of apoptosis by linoleic acid is associated with the modulation of Bcl-2 family and Fas/FasL system and activation of caspases in AGS human gastric adenocarcinoma cells. J Med Food. 2008, 11, 1-8. Lee, S. Y.; Rhee, Y. H.; Jeong, S. J.; Lee, H. J.; Lee, H. J.; Jung, M. H.; Kim, S. H.; Lee, E. O.; Ahn, K. S.; Ahn, K. S.; Kim, S. H. Hydrocinchonine, cinchonine, and quinidine potentiate paclitaxel-induced cytotoxicity and apoptosis via multidrug resistance reversal in MES-SA/Dx5 uterine sarcoma cells. Toxicol. 2011, 26, 424-431. Ling, Y. H.; El-Naggar, A. K.; Proebe, W.; Perez-Soler, R. Cell cycle-dependent cytotoxicity, G2/M phase arrest, and disruption of p34cdc2/cyclin B1 activity induced by doxorubicin in synchronized P388 cells. Mol Pharmaco.l 1996, 49, 832-841. Liotta L.A. Tumor invasion and metastases-role of the extracellular matrix: Rhoads Memorial Award lecture. Cancer research. 1986, 46, 1-7. Longley, D. B.; Johnston, P. G: Molecular mechanisms of drug resistance. J Pathol. 2005, 205, 275-292. Lowe, S. W.; Lin, A. W. Apoptosis in cancer. Carcinogenesis. 2000, 21, 485-495. Lu, X.; Yu, H.; Ma, Q.; Shen, S.; Das, U. N. Linoleic acid suppresses colorectal cancer cell growth by inducing oxidant stress and mitochondrial dysfunction. Lipids in Health and Disease. 2010, 9:106. Lupertz, R.; Watjen, W.;, Kahl, R.; Chovolo, Y. Dose- and time-dependent effects of doxorubicin on cytotoxicity, cell cycle and apoptotic cell death in human colon cancer cells. Toxicology. 2010, 271, 115-121. Matos, M. F. C.; Leite, L. I. S. P.; Brustolim, D.; de Siqueira, J. M.; Carollo ,C.A.; Hellmann A.R.; Pereira N. F. G.; da Silva D. B. Antineoplastic activity of selected constituents of Duguetia glabriuscula. Fitoterapia. 2006, 77, 227-229. Matsuda, H.; Strebel, F. R.; Kaneko, T.; Stephens, L. C.; Danhauser, L. L.; Jenkins, G. N.; Toyota, N.; Bull, J. M. Apoptosis and necrosis occurring during different stages of primary and metastatic tumor growth of a rat mammary adenocarcinoma. Anticancer Res. 1996, 16, 1117-1121. McCann, S. E.; Freudenheim, J. L.; Marshall, J. R.; Graham, S. Risk of human ovarian cancer is related to dietary intake of selected nutrients, phytochemicals and food groups. J Nutr. 2003,133, 1937-1942. Mendilaharsu, M.; Stefani, E.D.; Deneo-Pellegrini, H.; Carzoglio, J.; Ronco, A. Phytosterols and risk of lung cancer: A case-control study in Uruguay. Lung Cancer. 1998, 21, 37-45. Minow, R. A.; Benjamin, R. S.; Lee, E. F.; Gottlieb, J. A. Adriamycin cardiomyopathy — risk factors. Cancer. 1977, 39, 1397-402. Moon, D.; Lee, K.; Choi, Y. H.; Kim, G. β-Sitosterol-inducedapoptosis is mediated by the activation of ERK and the downregulationn of Akt in MCA-102 murine fibrosarcoma cells. Int Immunopharmacol. 2007, 7, 1044-1053. Moon, D. O.; Kim, M. O.; Choi, Y. H.; Kim, G.Y. beta-Sitosterol induces G2/M arrest, endoreduplication, and apoptosis through the Bcl-2 and PI3K/Akt signaling pathways. Cancer Lett. 2008, 264, 181-191. Nautiyal, J. T.; Kanwar, S. S.; Yu, Y.J.; Adhip PN Majumdar. Combination of dasatinib and curcumin eliminates chemo-resistant colon cancer cells. Journal of Molecular Signaling. 2011, 6: 7. Nguyen, A. T.; Malonne, H.; Duez, P.; Vanhaelen-Fastre, R.; Vanhaelen, M.; Fontaine ,J. Cytotoxic constituents from Plumbago zeylanica. Fitoterapia. 2004, 75, 500-504. Nicotera, P.; Leist, M.; Ferrando-May, E. Apoptosis and necrosis: different execution of the same death. Biochem. Soc. Symp. 1999, 66, 69-73. Numata, M.; Yamamoto, A.; Moribayashi. A.; Tamada, H. Antitumor compounds isolated from the Chinese herbal medicine Coix lachryma-jobi. Planta Med. 1994, 60, 356-359. Nurulita, N. A.; Meiyanto, E.; Sugiyanto ; Matsuda, E.; Kawaichi, M. Gynura procumbens modulates the microtubules integrity and enhances distinct mechanism on doxorubicin and 5-flurouracil-induced breast cancer cell death. Orient Pharm Exp Med. 2012, 63: 5. Ostlund, R. E. Phytosterols in human nutrition. Annu Rev. Nutr. 2002, 22, 533-549. Park, C.; Moon, D.; Rhu, C.; Choi, B. T.; Lee, W. H.; Kim, G. β-Sitosterol induces anti-proliferation and apoptosis in human leukemic U937 cells through activation of caspase-3 and induction of Bax/Bcl-2 ratio. Biol Pharm Bull. 2007, 30, 1317-1323. Parone, P. A.; James, D.; Martinou, J. C. Mitochondria: regulating the inevitable. Biochimie. 2002, 84, 105-111. Paulovich, A. G.; Toczyski, D. P.; Hartwell, L. H. When checkpoints fail. Cell. 1997, 88, 315-321. Pawan K. Singal; D. S.; Natasha Ilickovic, M. D. Doxorubicin induced cardiomyopathy. N Engl J Med. 1998, 339, 900-905. Pihkala, J.; Saarinen, U. M.; Lundstrom, U. Myocardial function in children and adolescents after therapy with anthracyclines and chest irradiation. Eur J Cancer. 1996, 32, 97-103. Praga, C.; Beretta, G.; Vigo, P. L. Adriamycin cardiotoxicity: a survey of 1273 patients. Cancer Treat Rep. 1979, 63, 827-834. Sanders, D. J.; Minter, H. J.; Howes, D.; Hepburn, P. A. The safety evaluation of phytosterol esters Part 6 The comparative absorption and tissue distribution of phytosterols in the rat. Food Chem Toxicol. 2000, 38, 485-491. Satoh, M. S.; Poirier, G. G.; Lindahl, T. Dual function for poly (ADP-ribose) synthesis in response to DNA strand breakage. Biochemistry. 1994, 33, 7099-7106. Schafer, K. A. Review article the cell cycle: a review. Vet Pathol. 1998, 35, 461-478. Searle, J.; Kerr, J. F.; Bishop, C. J. Necrosis and apoptosis: distinct modes of cell deathwith fundamentally different significance. Pathol Annu. 1982, 17, 229-259. Setzer, W. N.; Setzer, M. C.; Schmidt ,J. M;, Moriarity, D. M.; Vogler, B.; Reeb, S.; Holmes, A. M.; Haber, W. A. Cytotoxic components from the bark of Stauranthus perforates from Monteverde. Planta Med. 2000, 66, 493-494. Singal, P. K.; Iliskovic, N. Current Concepts: Doxorubicin-Induced Cardiomyopathy. N Engl J Med. 1998, 24, 900-905 Siu, W. Y.; Yam, C. H.; Poon, R. Y.; G1 versus G2 cell cycle arrest after adriamycin induced damage in mouse Swiss3T3 cells. FEBS Lett. 1999, 461, 299-305. Soria, J. C.; Kim, E. S.; Fayette, J.; Lantuejoul, S.; Deutsch, E.; Hong, W. K. Chemoprevention of lung cancer Lancet Oncol. 2003, 4, 659-669. Sporn, M. B. Approaches to prevention of epithelial cancer during the preneoplastic period. Cancer Res. 1976, 36, 2699-2702. Stein, U.; Walther, W.; Lemm, M.; Naundorf, H.; Fichtner, I. Development andcharacterisation of novel human multidrug resistant mammary carcinoma lines in vitro and in vivo. Int J Cancer. 1997, 72, 885-891. Stein, E. M.; Andreguetti, D. X.; Rocha ,C. S.; Fujii, Mu. T.; Baptista, M. S.; Colepicolo, P.; Indig, G. L. Search for cytotoxic agents in multiple Laurencia complex seaweed species(Ceramiales, Rhodophyta) harvested fromnthe atlantic ocean with emphasis on the Brazilian State of Espirito Santo. Brazilian Journal of Pharmacognosy. 2011, 21, 239-243. Stewart, Z. A.; Westfall, M. D.; Pietenpol, J. A. Cell-cycle dysregulation and anticancer therapy. Trends Pharmacol. 2003, 24, 139-145. Strom, S. S.; Yamamura, Y.; Duphorne, C. M.; Spitz, M. R.; Babaian, R. J.; Pillow, P. C.; Hursting, S. D. Phytoestrogen intake and prostate cancer: a case-control study using a new database. Nutrition and cancer. 1999, 33, 20-25 Surh, Y. J. Molecular mechanisms of chemopreventive effects of selected dietary and medicinal phenolic substances. Mutat. Res. 1999, 428, 305-327. Takeshita, H.; Gebhardt, M. C.; Springfield, D. S.; Kusuzaki, K.; Mankin, H. J. Experimental models for the study of drug resistance in osteosarcoma: P-glycoprotein-positive, murine osteosarcoma cell lines. J Bone Joint Surg Am 1996, 78, 366-375. Tewari, M.; Quan, L. T.; O'Rourke, K.; Desnoyers, S.; Zeng, Z.; Beidler, D. R.; Poirier, G. G.; Salvesen, G. S.; Dixit, V. M. Yama/CPP32 beta, a mammalian homolog of CED-3, is a CrmA-inhibitable protease that cleaves the death substrate poly (ADP-ribose) polymerase. Cell. 1995, 81, 801-809. Titus, B.; Schwartz, M. A.; Theodorescu, D. Rho proteins in cell migration and metastasis. Critical reviews in eukaryotic gene expression. 2005, 15(2):103-14. Tokuda, H.; Matsumoto, T.; Konoshima, T.; Kozuka, M.; Nishino, H.; Iwashima, A. Inhibitory effect on Epstein-Barr virus activation and anti-tumor promoting activities of Coix seed. Planta Med. 1990, 56, 653-654. Tsao, A. S.; Kim, E. S.; Hong, W. K. Chemoprevention of Cancer. CA Cancer J Clin. 2004, 54, 150-180. Reed, J. C. Bcl-2 family proteins. Oncogene. 1998, 17, 3225-3236. Rouyanne, T. R. ; Henk, C. M. van der Knaap; Guus, S. M. J. E. Duchateau; Linsie, M.; Peter, L. Z.; Johanna, M. G.; Elke, A. T. Continuous dose –response relationship of the LDL-cholesterol-lowering effect of phytosterol intake. J. Nutr. 2009 ,139, 1-14. Ryan, E.; Galvin, K.; O’Connor, T. P.; Maguire A. R.; O’Brien N. M. Phytosterol, squalene, tocopherol content and fatty acid profile of selected seeds, grains, and legumes. Plant Foods Hum Nutr. 2007, 62, 85-91. Ukita, T.; Tanimura, A. Studies on the anti-tumor component in the seeds of Coix lachryma-jobi L. var. ma-yuen (Roman) stapf I. Isolation and anti-tumor activity of coixenolide. Chem Pharm Bull. 1961, 9, 43-46. Van der Valk, P.; Van Kalken, C. K.; Ketelaars, H.; Broxterman ,H. J.; Scheffer, G.; Kuiper, C. M.; Tsuruo, T.; Lankelma, J.; Meijer, C. J.; Pinedo, H. M.; Scheper, R. J.. Distribution of multi-drug resistance-associated P-glycoprotein in normal and neoplastic human tissues. Analysis with 3 monoclonal antibodies recognizing different epitopes of the P-glycoprotein molecule. Ann Oncol. 1990, 1, 56-64 Vivancos, M.; Moreno, J. J. β-Sitosterol modulates antioxidant enzyme response in RAW 264 7 macrophages. Free Radic Biol Med. 2005, 39, 91-97. Von Hoff, D. D.; Rozencweig, M.; Layard, M.; Slavik, M.; Muggia, F. M. Daunomycin -induced cardiotoxicity in children and adults: a review of 110 cases. Am J Med. 1977, 62, 200-208. Von Hoff, D. D.; Layard, M. W.; Basa, P. Risk factors for doxorubicin induced congestive heart failure. Ann Intern Med. 1979, 91, 710-717. Wadler, S.; Wiernik, P. H. Partial reversal of doxorubicin resistance by forskolin and 1,9-dideoxyforskolin in murine sarcoma S180 variants. Cancer Res 1988, 48, 539-543. Wang, H. M.; Pan, J. L.; Chen, C. Y.; Chiu, C. C.; Yang, M. H.; Chang, H. W.; Chang, J. S. Identification of anti-lung cancer extract from Chlorella vulgaris C-C by antioxidant property using supercritical carbon dioxide extraction. Process Biochemistry. 2010, 45, 1865-1872. Weinberg, W. C.; Denning, M. F. P21Waf1 control of epithelial cell cycle and cell fate. Crit. Rev. Oral Biol. Med. 2002, 13, 453-464. Woo, J. H.; Li, D.; Wilsbach, K.; Orita, H.; Coulter, J.; Tully, E.; Kwon, T. K.; Xu, S.; Gabrielson, E. Coix seed extract, a commonly used treatment for cancer in China, inhibits NFkappaB and protein kinase C signaling. Cancer Biol Ther. 2007, 6, 2005-2011. Woyengo, T. A.; Ramprasath, V. R.; Jones, P. J. H. Anticancer effects of phytosterols. European Journal of Clinical Nutrition. 2009, 63, 813-820. Wyllie, A. H.; Kerr, J. F.; Currie, A. R. Cell death: The significance of apoptosis. Int Rev Cytol. 1980, 68, 251-306. Yang, C. L.; Liu, Y. Y.; Ma, Y. G.; Xue, Y. X.; Liu, D. G.; Ren,Y.; Liu, X. B.; Li, Y.; Li, Z. Curcumin blocks small cell Lung cancer cells migration, invasion, angiogenesis, cell cycle and neoplasia through janus kinase-STAT3 signalling pathway. PLoS ONE. 2012,7, e37960. | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/64221 | - |
| dc.description.abstract | 癌症從民國71年以來一直位居十大死因之首，目前治療方式中化學治療是其中一種。然而，在化學治療期間會產生大小不等的副作用及多重藥物阻抗性(Multi-drug resistance, MDR)，造成化療效果不佳。MDR 目前產生機制尚未完全明瞭，但有許多研究顯示，在腫瘤細胞內會有大量抗藥性蛋白P-醣蛋白(P-glycoprotein, P-gp)表現，因而產生抗藥性，而且P-gp 表現的癌細胞會對凋亡作用產生阻抗，也會造成藥物阻抗性。另外，化療效果不佳和腫瘤細胞轉移(tumor metastasis)也有密切關係。過去研究指出薏苡籽實萃取物具有抑癌作用，因此，本研究擬探討薏苡種皮乙醇萃取物結合抗癌藥物doxorubicin 對子宮惡性肉瘤細胞生長抑制之影響。結果顯示，(1)在薏苡種皮乙醇萃取物中以hexane 區分層(ATE-Hex)的抑制效果最佳，並且結合doxorubicin 後計算combination index (CI) ，顯示具有相乘作用；(2)給予ATE-Hex 有減少P-gp 之表現及減少轉移(migration) 之作用；(3)兩者結合在細胞週期結果可看到在48、72小時sub G1上升及western blot 結果顯示PARP 被截切；(4)抑癌活性分析部分：植物固醇抑制效果較脂肪酸好，其中又以campesterol 與β-sitosterol 的抑制效果最好。根據以上結果推測，薏苡種皮乙醇萃取物可抑制人類子宮惡性肉瘤細胞生長，若結合抗癌藥物doxorubicin 可減少藥物阻抗性，且具相乘作用。 | zh_TW |
| dc.description.abstract | Cancer has been the top ten causes of death in Taiwan from 1982. Chemotherapy is one of the cancer treatments. However, chemotherapy will cause many side effects and multiple drug resistance (MDR). These are the main poor effects of chemotherapy. MDR can be the result of a variety of mechanisms that are not completely understood, but many studies have shown P-glycoprotein expression was higher in tumor cells, and it induced MDR. On the other hand, there are evidences that P-gp positive cells are resistant to apoptosis. In addition, it’s also closely related between the poor effects of chemotherapy and tumor metastasis. Previous studies revealed that adlay seed extracts could have anti-cancer activity. Thus, this study will investigate that combination of adlay testa ethanolic extracts (ATE) and doxorubicin has on the growth inhibition of human uterine sarcoma cells. Results demonstrated that (1) ATE-Hex had the best effects of inhibition on MES-SA and MES-SA/Dx5 cells. Co-treatment of ATE-Hex and sub-toxic doxorubicin could synergistically or additively inhibit cancer cells proliferation. (2) ATE-Hex reduced the rhodamine efflux in MES-SA/Dx5 cells, indicated that ATE-Hex could reduce P-gp expression. ATE-Hex also could inhibit migration of MES-SA and MES-SA/Dx5 cancer cells. (3) Combination of ATE-Hex and doxorubicin induced apoptosis by increasing sub G1 phase and PARP being cleaved. (4) Analysis of anti-cancer activity, phytosterols had better inhibition on cancer cells growth than fatty acids, especially campesterol and β-sitosterol. These present findings showed that ATE could inhibit on the growth of human uterine sarcoma cancer cells. Furthermore, the combination of ATE and doxorubicin could decrease drug resistance and increase synergistic effect. | en |
| dc.description.provenance | Made available in DSpace on 2021-06-16T17:35:30Z (GMT). No. of bitstreams: 1 ntu-101-R99641033-1.pdf: 42922422 bytes, checksum: c43cd20b91620ae507fa71c05e64ee53 (MD5) Previous issue date: 2012 | en |
| dc.description.tableofcontents | 目錄
中文摘要....................................................I Abstract..................................................II 縮寫對照表................................................III 目錄.......................................................Ⅵ 圖目錄......................................................X 表目錄........................................................XI 第一章 前言.................................................1 第二章 文獻回顧..............................................2 一、薏苡籽實介紹及相關研究.....................................2 (一) 薏苡簡介...............................................2 (二) 薏苡機能性之研究.........................................3 (三) 薏苡油脂之成分分析與功效性.................................7 (四) 植物固醇簡介...........................................10 二、癌症簡介................................................16 (一) 癌症 ..................................................16 (二) 腫瘤細胞形成及成因......................................17 (三) 人類子宮惡性肉瘤細胞株簡介................................19 (四) 腫瘤抗藥性概念..........................................20 (五) 癌細胞的侵襲與轉移......................................21 (六) 癌症化學預防...........................................22 (七) 組合指數(combination index, CI) ......................23 三、癌症治療藥物Anthracycline 家族-Doxorubicin...............24 (一) Doxorubicin臨床效用及病理機轉...........................24 (二) Doxorubicin造成之副作用................................25 四、癌症治療機制探討.........................................27 (一) 細胞凋亡..............................................27 (二) 細胞週期調控...........................................30 第三章 研究動機與實驗架構.....................................32 一、研究動機................................................32 二、研究架構................................................34 第四章 材料與方法............................................34 一、實驗材料................................................34 (一) 實驗樣品..............................................34 (二) 實驗細胞株.............................................34 (三) 化學藥品及試劑..........................................34 (四) 儀器設備..............................................37 二、實驗方法................................................39 (一) 薏苡種皮乙醇萃取物區分層之製備.............................39 (二) 細胞培養與繼代..........................................40 (三) 細胞存活率測定(MTT assay)...............................40 (四) 組合指數分析(Combination index assay)..................41 (五) P-glycoprotein 轉運能力分析(Rhodamine 123 efflux assay) ..........................................................42 (六) 細胞移行性分析(Cell migration assay)....................43 (七) 細胞週期分析(Cell cycle analysis)......................43 (八) 蛋白質萃取及定量........................................44 (九) 西方點墨法(Western blotting)...........................45 (十) 薏苡種皮乙醇萃取物正己烷區分物薄層分析(TLC spot)............48 (十一) 薏苡種皮乙醇萃取物正己烷區分層氣相層析儀分析................48 (十二) 統計分析.............................................50 第五章 實驗結果.............................................51 一、薏苡乙醇萃取物對MES-SA 與MES-SA/Dx5 人類子宮惡性肉瘤細胞生長抑制作用......................................................51 二、薏苡種皮乙醇萃取物不同極性區分物對MES-SA 與MES-SA/Dx5 人類子宮惡性肉瘤細胞及HutSMC 正常人類子宮平滑肌細胞生長抑制作用.............53 三、Doxorubicin 對MES-SA 與MES-SA/Dx5 人類子宮惡性肉瘤細胞生長抑制作用......................................................57 四、薏苡種皮乙醇萃取物正己烷區分物與doxorubicin 合併處理對MES-SA 與MES-SA/Dx5 人類子宮惡性肉瘤細胞生長抑制作用....................59 五、P-glycoprotein 轉運能力分析及蛋白表現之影響................64 六、薏苡種皮乙醇萃取物正己烷區分物對於細胞移行性之影響.............67 七、薏苡種皮乙醇萃取物正己烷區分物與 doxorubicin 合併處理對MES-SA 與MES-SA/Dx5 人類子宮惡性肉瘤細胞細胞週期之影響..................69 八、薏苡種皮乙醇萃取物正己烷區分物與doxorubicin 合併處理對MES-SA 與MES-SA/Dx5 人類子宮惡性肉瘤細胞凋亡相關蛋白之影響...............74 九、薏苡種皮乙醇萃取物正己烷區分物薄層分析(TLC spot).............76 十、薏苡種皮乙醇萃取物正己烷區分物氣相層析儀分析及活性分析..........76 (一) 植物固醇成分與活性分析...................................77 (二) 脂肪酸成分與活性分析.....................................82 第六章 討論................................................86 一、薏苡種皮乙醇萃取物正己烷區分物、doxorubicin以及合併處理對MES-SA 與MES-SA/Dx5 人類子宮惡性肉瘤細胞生長抑制作用...................86 二、P-glycoprotein 轉運能力分析及蛋白表現之影響.................87 三、薏苡種皮乙醇萃取物正己烷區分物對於細胞移行性之影響..............88 四、薏苡種皮乙醇萃取物正己烷區分物與doxorubicin 合併處理MES-SA 與MES-SA/Dx5 人類子宮惡性肉瘤細胞對細胞週期及細胞凋亡之影響.........89 五、薏苡種皮乙醇萃取物正己烷區分物抑制MES-SA 與MES-SA/Dx5 人類子宮惡性肉瘤細胞活性物質之探討......................................92 第七章 結論................................................95 第八章 參考文獻.............................................96 | |
| dc.language.iso | zh-TW | |
| dc.subject | 薏苡種皮 | zh_TW |
| dc.subject | 多重藥物阻抗性 | zh_TW |
| dc.subject | 凋亡 | zh_TW |
| dc.subject | 轉移 | zh_TW |
| dc.subject | 植物固醇 | zh_TW |
| dc.subject | adlay testa | en |
| dc.subject | multi-drug resistance | en |
| dc.subject | apoptosis | en |
| dc.subject | migration | en |
| dc.subject | phytosterol | en |
| dc.title | 薏苡種皮乙醇萃取物結合doxorubicin抑制人類子宮惡性肉瘤細胞生長之探討 | zh_TW |
| dc.title | Combination effects of adlay testa extracts and doxorubicin on the growth inhibition of human uterine sarcoma cancer cells | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 100-2 | |
| dc.description.degree | 碩士 | |
| dc.contributor.coadvisor | 夏詩閔(Shih-Min Hsia) | |
| dc.contributor.oralexamcommittee | 羅翊禎(Yi-Chen Lo),龔瑞林(Jui-Lin Kung),郭靜娟(Ching-Chuan Kuo) | |
| dc.subject.keyword | 薏苡種皮,多重藥物阻抗性,凋亡,轉移,植物固醇, | zh_TW |
| dc.subject.keyword | adlay testa,multi-drug resistance,apoptosis,migration,phytosterol, | en |
| dc.relation.page | 110 | |
| dc.rights.note | 有償授權 | |
| dc.date.accepted | 2012-08-15 | |
| dc.contributor.author-college | 生物資源暨農學院 | zh_TW |
| dc.contributor.author-dept | 食品科技研究所 | zh_TW |
| 顯示於系所單位： | 食品科技研究所 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-101-1.pdf 未授權公開取用 | 41.92 MB | Adobe PDF |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。